过去一年中添加的文章，按日期排序
Risk Factors for Psoriasis Flares: A Narrative Review
L Potestio, G Lauletta, N Tommasino… - … : Targets and Therapy, 2024 - Taylor & Francis
40 天前 - … , immunotherapy for oncologic disease, Covid-19, and vaccines) defined as those
newly identified risk factors. Accurate patient information and monitoring of risk factors as well …
newly identified risk factors. Accurate patient information and monitoring of risk factors as well …
[引用][C] Comment on: Clinical Characteristics, Diagnosis, and Treatments for COVID-19
Y Wen, X Hu - Current Medical Science, 2024 - Springer
41 天前 - … immunotherapy … COVID-19-associated IRIS (table 1). The heterogeneity of IRIS
presents a challenge for its diagnosis and treatment. Among patients with aggravated COVID-19 …
presents a challenge for its diagnosis and treatment. Among patients with aggravated COVID-19 …
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction …
X Zhang, Y Wang, X Xiang, H Pan, J Zhang, X Chen… - 2024 - ascopubs.org
41 天前 - … 6 pts were excluded due to treatment interruptions caused by Covid-19 …
immunotherapy to VEGFR-2 targeting therapy could be a potential strategy to overcome …
immunotherapy to VEGFR-2 targeting therapy could be a potential strategy to overcome …
Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous …
K Yang, X Zhang, Z Zhang, B Wu, J Huang, G Peng… - 2024 - ascopubs.org
41 天前 - … findings, with a continuation of immunotherapy for an additional nine cycles. The …
storm and pulmonary infection), 1 postoperative COVID-19-related sudden death, along with …
storm and pulmonary infection), 1 postoperative COVID-19-related sudden death, along with …
Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).
41 天前 - … We conducted a phase II single-arm neoadjuvant trial of pembrolizumab (P) in
patients … Three patients died prior to definitive surgery: 2 from COVID-19, a third from a NSTEMI …
patients … Three patients died prior to definitive surgery: 2 from COVID-19, a third from a NSTEMI …
Immune response to SARS-CoV-2 vaccine administered to patients with solid cancers under systemic treatment: A prospective, monocentric study (Immunocovid-19).
F Caputo, M Rotolo, E Carretto, L Albertazzi… - 2024 - ascopubs.org
41 天前 - … Background: Despite vaccination, COVID-19 could still … serology by means of
COVID-19 VIRCLIA® Monotest and … treated with chemo- (CT) or immunotherapy (IO). Then, we will …
COVID-19 VIRCLIA® Monotest and … treated with chemo- (CT) or immunotherapy (IO). Then, we will …
Patient-reported experience with an immunotherapy telehealth platform.
41 天前 - … those treated with single agent pembrolizumab. Because pembrolizumab is
administered as an … During the COVID-19 pandemic, the FDA granted accelerated approval for an …
administered as an … During the COVID-19 pandemic, the FDA granted accelerated approval for an …
Time-to-first treatment for new cancer diagnoses before and during the COVID-19 pandemic in Manitoba, Canada.
P Lambert, A Feely, K Galloway, O Bucher… - 2024 - ascopubs.org
41 天前 - … to health care during the COVID-19 pandemic raises the … the association between
the COVID-19 pandemic and time-… the association between the COVID-19 pandemic and time …
the COVID-19 pandemic and time-… the association between the COVID-19 pandemic and time …
Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.
X Cheng, Z Xu, C Hu, Y Zhang, Y Pengfei, Y Du… - 2024 - ascopubs.org
41 天前 - … COVID-19 was 44.44% (12/27), while the mPR rate in patients who have not been
infected with COVID-19 was 36.84% (7/19) (… who received preoperative immunotherapy plus …
infected with COVID-19 was 36.84% (7/19) (… who received preoperative immunotherapy plus …
Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a …
Y Jiang, G Qiu, J Li, J Wang, C Wang, J Wu, L Cheng… - 2024 - ascopubs.org
41 天前 - … and 2 patients did not receive immunotherapy due to pneumonia and myocarditis
after … (5.3%, 1/19, pneumonia) and died within 90 days of surgery due to COVID-19. Grade 1-…
after … (5.3%, 1/19, pneumonia) and died within 90 days of surgery due to COVID-19. Grade 1-…